A77 1726 increases IL-1 receptor antagonist (IL-1Ra) secretion in human synovial fibroblasts and articular chondrocytes in the presence of tumour necrosis factor (TNF)-α
Figures are generally photos, graphs and static images that would be represented in traditional pdf publications.
Taken from "The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes"
Arthritis Research & Therapy 2004;6(3):R181-R189.
Published online 19 Feb 2004
Copyright © 2004 Palmer et al., licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.Human osteoarthritis (OA) synovial fibroblasts (passage 2) and de-differentiated human OA articular chondrocytes (passage 7) were stimulated (closed symbols) or not (open symbols) with 10 ng/ml TNF-α alone or in combination with 50 μmol/l or 100 μmol/l A77 1726 for 48 hours. A77 1726 was added 2 hours before stimulation with TNF-α. IL-1Ra concentrations in culture supernatants were measured by ELISA. Results are represented as means ± SEM of three determinations in a representative experiment. A similar dose dependency was observed in cells obtained from three different donors (three OA samples) for synovial fibroblasts and three different donors (three OA samples) for de-differentiated chondrocytes. *< 0.001 versus control; < 0.001 versus TNF-α alone.